Your browser doesn't support javascript.
loading
Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes.
Shivakoti, Rupak; Dalli, Jesmond; Kadam, Dileep; Gaikwad, Sanjay; Barthwal, Madhusudan; Colas, Romain A; Mazzacuva, Francesca; Lokhande, Rahul; Dharmshale, Sujata; Bharadwaj, Renu; Kagal, Anju; Pradhan, Neeta; Deshmukh, Sona; Atre, Sachin; Sahasrabudhe, Tushar; Kakrani, Arjun; Kulkarni, Vandana; Raskar, Swapnil; Suryavanshi, Nishi; Chon, Sandy; Gupte, Akshay; Gupta, Amita; Gupte, Nikhil; Arriaga, María B; Fukutani, Kiyoshi F; Andrade, Bruno B; Golub, Jonathan E; Mave, Vidya.
Affiliation
  • Shivakoti R; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Columbia University Mailman School of Public Health, New York, NY, USA. Electronic address: rs3895@cumc.columbia.edu.
  • Dalli J; William Harvey Research Institute, Queens Mary University of London, London, UK.
  • Kadam D; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Gaikwad S; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Barthwal M; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, India.
  • Colas RA; William Harvey Research Institute, Queens Mary University of London, London, UK.
  • Mazzacuva F; William Harvey Research Institute, Queens Mary University of London, London, UK.
  • Lokhande R; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Dharmshale S; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Bharadwaj R; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Kagal A; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Byramjee-Jeejeebhoy Government Medical College, Pune, India.
  • Pradhan N; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Deshmukh S; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Atre S; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, India.
  • Sahasrabudhe T; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, India.
  • Kakrani A; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D.Y. Patil Vidyapeeth, Pune, India.
  • Kulkarni V; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Raskar S; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Suryavanshi N; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Chon S; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Gupte A; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Gupta A; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Gupte N; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
  • Arriaga MB; Instituto Goncalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil; Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil.
  • Fukutani KF; Instituto Goncalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil; Curso de Medicina, Faculdade de Tecnologia e Ciências, Salvador, Brazil.
  • Andrade BB; Instituto Goncalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil; Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research, Fundação José Silveira, Salvador, Brazil; Curso de Medicina, Faculdade d
  • Golub JE; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Mave V; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Byramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Prostaglandins Other Lipid Mediat ; 147: 106398, 2020 04.
Article in En | MEDLINE | ID: mdl-31726221
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution of inflammation) lipid mediators in individuals with TB and TB-DM. A nested cross-sectional study of 40 individuals (20 newly diagnosed DM and 20 without DM) was conducted within a cohort of individuals with active drug-susceptible treatment-naïve pulmonary TB. Lipid mediators were quantified in serum samples through lipid mediator profiling. We conducted correlation-based analysis of these mediators. Overall, the arachidonic acid-derived leukotriene and prostaglandin families were the most abundant pro-inflammatory lipid mediators, while lipoxins and maresins families were the most abundant pro-resolving lipid mediators in individuals with TB and TB-DM. Individuals with TB-DM had increased correlations and connectivity with both pro-inflammatory and pro-resolving lipid mediators compared to those with TB alone. We identified the most abundant lipid mediator metabolomes in circulation among individuals with TB and TB-DM; in addition, our data shows a substantial number of significant correlations between both pro-inflammatory and pro-resolving lipid mediators in individuals with TB-DM, delineating a molecular balance that potentially defines this comorbidity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Biomarkers / Inflammation Mediators / Diabetes Mellitus, Type 2 / Inflammation Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Prostaglandins Other Lipid Mediat Journal subject: ENDOCRINOLOGIA Year: 2020 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Biomarkers / Inflammation Mediators / Diabetes Mellitus, Type 2 / Inflammation Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Prostaglandins Other Lipid Mediat Journal subject: ENDOCRINOLOGIA Year: 2020 Document type: Article Country of publication: Estados Unidos